Efficacy and safety of semaglutide in non-alcoholic fatty liver disease

Figure 1 PRISMA flow diagram of study selection. WHO: World health organization.

Figure 2 Effect of semaglutide on histologic parameters. A: Resolution of non-alcoholic steatohepatitis (NASH) with no worsening of liver fibrosis; B: Improvement in liver fibrosis stage without worsening of NASH; C: Improvement in steatosis; D: Improvement in lobular inflammation; E: Improvement in hepatocellular ballooning. 95%CI: 95% confidence intervals.

Figure 3 Effect of semaglutide on radiologic parameters. A: Liver stiffness assessed by magnetic resonance enterography or Fibroscan; B: Liver steatosis assessed by MRI proton density fat fraction. 95%CI: 95% confidence intervals.

Figure 4 Effect of semaglutide on liver enzymes. A: Alanine aminotransferase; B: Aspartate aminotransferase. 95%CI: 95% confidence intervals.

Figure 5 Effect of semaglutide on cardiometabolic parameters. A: Body weight; B: HgA1c in patients with type 2 diabetes (T2DM) vs without T2DM. 95%CI: 95% confidence intervals.

Figure 6 Adverse events with semaglutide. A: Gastrointestinal related side effects; B: Serious adverse events. 95%CI: 95% confidence intervals.